ArticleESMO open2025
Performance and considerations in the use of diagnostic mutation panels for clonality testing in non-small-cell lung carcinoma.
Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lepidic and alveolar subepithelial squamous cell carcinoma: expansion of the concept of peripheral squamous cell carcinoma with proposal for revised terminology based on morphologic, immunophenotypic, and clinical analysis of 22 cases.Virchows Archiv : an international journal of pathology · 2026Article
- The Added Value of Genome-Wide Copy Numbers to Objectively Resolve Clonality of Multiple Tumors With Pulmonary Involvement and Ambiguous or Inconclusive Mutational Diagnosis.JTO clinical and research reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNext-generation sequencing (NGS) mutation panels are widely implemented and commonly applied to aid clonality classification for non-small-cell lung carcinoma (NSCLC) patients with multiple tumors. Performance of different NGS panels for clonality classification, however, remains unresolved.
methodsWe assembled 210 primary and metastatic pairs from lung adenocarcinoma (LUAD) and lung squamous-cell carcinomas (LUSC) of the TRACERx421 cohort for which gold standard clonality was confirmed by whole exome sequencing. We used four NGS panels ranging from 12 to 523 genes to determine clonality using the 2024 International Association for the Study of Lung Cancer (IASLC) recommendations.
resultsWith an oncogene panel, 30% LUAD and 74% LUSC pairs remained inconclusive with, respectively, 2% and 0% misclassified. Addition of tumor suppressor genes results in 5% LUAD and 5% LUSC inconclusive and, respectively, 2% and 1% misclassified. For large panels, 0%-1% was inconclusive and 1% misclassified for both LUAD and LUSC. Misclassifications occurred due to discordant KRAS mutations in clonal pairs or coincidentally shared PIK3CA mutations in non-clonal pairs.
conclusionOncogene panels result in many inconclusive results, most of which can be resolved by adding tumor suppressor genes. Notwithstanding, 1%-2% of patients remain challenging. Large NGS panels detect mutations in more genes than the IASLC recommendations, allowing definitive clonality classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.